Pure Global

PTCA Dilatation Catheter - India CDSCO Medical Device Registration

PTCA Dilatation Catheter is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/MD/2020/000228_202f771d562f6249579206f69258f1df_e2cfee98a0bf688a80d66155589d4c9c. This device is marketed under the brand name Focus np, Abluminus np, Cynosure. The license holder is Envision Scientific Pvt. Ltd., and it is classified as Device Class Class D. The approving authority is Central Drug Standards Control Organization, Ahmedabad.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class D
PTCA Dilatation Catheter
UID: MFG/MD/2020/000228_202f771d562f6249579206f69258f1df_e2cfee98a0bf688a80d66155589d4c9c

Brand Name

Focus np, Abluminus np, Cynosure

Device Class

Class D

Approving Authority

Central Drug Standards Control Organization, Ahmedabad

Product Information

The PTCA dilatation catheter is intended for use in treatment of patient with clinical symptoms of myocardial ischemia related to pathological conditions of one or more coronary arteries. The PTCA Dilatation catheter is therefore indicated to dilate the diseased segment(Focus np, Abluminus np, Cynosure) in a coronary artery or a coronary bypass, to improve myocardial perfusion. The PTCA Dilatation catheter is indicated for patients with following criteria: ๏‚ง Patient must be judged to be acceptable candidate for coronary bypass surgery. ๏‚ง Patients with single vessel atherosclerotic lesion (Focus np, Abluminus np, Cynosure), nonโ€calcified, subtotal and accessible to dilatation with guidewire and catheter. ๏‚ง Certain multiโ€vessel diseased patient may also be candidates for this procedure. Certain patients, who have undergone previous coronary bypass surgery with recurrence of symptoms and progression of the disease in the coronary artery, or stenosis and closure of the grafts, may also be candidates

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing